The tolerability and efficacy of Hyalubrix® in osteoarthritis

Submission date	Recruitment status No longer recruiting	Prospectively registered		
26/05/2009		☐ Protocol		
Registration date 21/07/2009	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
11/10/2011	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Calogero Foti

Contact details

Azienda Ospedaliera Universitaria Policlinico Torvergata Viale Oxford 81 Rome Italy 00133

Additional identifiers

Protocol serial number

Prot. Q47.2005.01

Study information

Scientific Title

A prospective observational study of the tolerability and efficacy of injectable hyaluronic acid therapy (Hyalubrix®) in osteoarthritis

Acronym

PEGASO

Study objectives

Evaluation of the use of Hyalubrix®, under EC indications for registration, with particular reference to therapy tolerability.

Ethics approval required

Old ethics approval format

Ethics approval(s)

- 1. Azienda Ospedaliera Universitaria Policlinico Tor Vergata approved on the 20th June 2006
- 2. Comitato Etico Novara approved on the 9th June 2006 (ref: 1069/CE). Final approval given on the 27th July 2006 (ref: 1127/CE)

Study design

Observational prospective longitudinal multicentre study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Osteoarthritis

Interventions

Four visits were scheduled:

Visit one: enrolment and start of therapy

Visit two: during study treatment Visit three: during study treatment

Visit four: patient's final evaluation, 2 weeks from third injection

At each visit, the following tools have also been adopted to evaluate the most significant effects of chronic pain on the social life and personality of the patient:

- 1. Pain at rest: Visual Analogue Scale (VAS)
- 2. Pain during motion: VAS
- 3. Functional Disability Index: Health Assessment Questionnaire (HAQ)
- 4. Quality of Life: EuroQoL

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Hyalubrix®

Primary outcome(s)

Adverse event notification.

Timepoints:

Visit 0: at baseline

Visit 2: one week after baseline Visit 3: one week after visit 2 Final visit: two weeks after visit 3

Key secondary outcome(s))

- 1. Evaluation of the medical device performance on pain during motion and at rest, determined by VAS and HAQ
- 2. Quality of life evaluation (by means of EuroQoL)

Timepoints:

Visit 0: at baseline

Visit 2: one week after baseline Visit 3: one week after visit 2 Final visit: two weeks after visit 3

Completion date

12/01/2008

Eligibility

Key inclusion criteria

- 1. Patients suffering from degenerative or mechanical arthropathies who were candidates for being treated with Hyalubrix®
- 2. Patients aged 18 years or older, either sex
- 3. Patients who signed informed consent form

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Infections located in the body area to be treated
- 2. Established sensitivity to hyaluronic acid or to other components of the product

Date of first enrolment

28/08/2006

Date of final enrolment

12/01/2008

Locations

Countries of recruitment

Italy

Study participating centre
Azienda Ospedaliera Universitaria
Rome
Italy
00133

Sponsor information

Organisation

Fidia Farmaceutici S.p.A. (Italy)

ROR

https://ror.org/00dy5wm60

Funder(s)

Funder type

Industry

Funder Name

Fidia Farmaceutici S.p.A. (Italy)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type

Details

Results article	results	01/09/2011		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes